Clinical Trial: A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo(R) in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer

U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07601620) titled 'A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo(R) in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer' on May 08.

Brief Summary: This is a study to compare the similarity in Pharmacokinetics (PK) profile of HLX319 vs. EU-Phesgo(R) in patients with HER2-positive early or locally advanced breast cancer .

Study Start Date: July 03

Study Type: INTERVENTIONAL

Condition: HER2 + Breast Cancer

Intervention: DRUG: HLX319

HLX319 is a biosimilar of pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)

DRUG: EU-Phesgo(R)

EU-Phesgo(R) is an or...